

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com/>

**Announcement regarding ActHib
(pediatric vaccine for the prevention of infections caused by *Haemophilus influenza* Type b)
launch date**

Tokyo, November 10, 2008 - Daiichi-Sankyo Co., Ltd. (Headquarters: Chuo-ku, Tokyo) announces that ActHIB which prevents the infectious diseases caused by *Haemophilus Influenza* Type b (License holder: Sanofi Pasteur Daiichi-Sankyo Vaccine Co., Ltd., Manufacturer: sanofi pasteur S.A (France), Distributor: Daiichi-Sankyo Co., Ltd. Approval: January 26, 2007) will be launched on December 19, 2008.